AUG 09, 2016 10:37 AM PDT

New Insight into Why Pancreatic Cancer Resists Treatments

WRITTEN BY: Xuan Pham
Pancreatic cancer has one of the worst mortality rates among all cancer types. It’s estimated that of the 53,000 Americans who will be diagnosed with pancreatic cancer this year, almost 79 percent will succumb from the disease. Why is this cancer so lethal and resistant to conventional therapies? Scientists from the University of Arizona say it’s because actual patient tumors are much more complex than the cell lines that are used to test the anticancer therapies. Their study urge for a more personalized approach to pancreatic cancer treatments if doctors are to outsmart the cancer.

Research urges more aggressive personalized approaches to pancreatic cancer | Image: wikimedia

"Pancreatic cancer is particularly challenging to treat," said Agnieszka Witkiewicz, professor of pathology and medicine at the University of Arizona. "Since there are no early detection tests, the majority of patients present with advanced disease. By that time, the tumor has accumulated multiple genetic changes selecting for resistance to many therapies."

"Currently there are no targeted therapies directly against the hallmark mutations common in pancreatic cancer, and each patient derived model we tested had its own unique therapeutic sensitivities," says author Erik Knudsen, a professor of medicine at the University of Arizona Cancer Center, and first author of the study. "I'd say that's why many pancreatic cancer clinical trials fail; it's that expectation that most tumors will respond in the same way to a drug."

When the research team analyzed patient-derived cancer lines versus conventional cancer cell lines, they found a big difference in response to cancer drugs. In particular, pancreatic cancer cell lines that have been standard in labs for years show more sensitivity to anticancer therapies. This is surprising given that these cell lines have gone through hundreds of generations in the course of being in the lab, acquiring more mutations with every division; and thus, should be less sensitive to treatments.
 

But, as the team reported, the patient-derived pancreatic cell lines were the ones that were less responsive to a library of cancer drugs. This suggests that each patient cancer is more complex than can be captured through traditional cell lines. It also points to more aggressive and tailored approaches for treatment.

"There's a bit of frustration with the current personalized medicine approach," said Erik Knudsen, senior author of the study. "If you sequence a hundred tumors from patients in the clinic, you might be able to treat one or two patients with the resulting information, because of the nature of pancreatic cancer genetics. Using new, patient-derived models fills in the gap for us and lets us guide our therapies with functional sensitivities to drugs, not with preconceived notions."

Additional source: Cell Press materials via EurekAlert!
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 21, 2018
Immunology
JUN 21, 2018
The Silver Tsunami: An Aging Immune System and Cancer
Why do cases of cancer become more common as we get older? Scientists interested in explaining the so-called “Silver Tsunami” phenomenon look t...
JUL 17, 2018
Cancer
JUL 17, 2018
Immunotherapy Diversification: From CAR-T cells to CAR-NK cells
New advances have made it possible for immunotherapy researchers to use natural killer cells, which are our body's normal defense for cancerous cells, to target tumors....
JUL 25, 2018
Neuroscience
JUL 25, 2018
Can CT Scans Increase the Risk of Brain Cancer?
Medical imaging has gone from fuzzy X-rays that didn't show much, to real-time functional MRI scans in just a few decades. Being able to see inside the...
JUL 31, 2018
Cancer
JUL 31, 2018
Protein Regulation of DNA Replication in Cancer Cells - A New Early Target for Broad Therapeutics?
DNA replication is a carefully regulated process in each cell of the body. Researchers are looking at the mechanism of DNA replication and associated proteins as a therapy target in cancer...
AUG 21, 2018
Immunology
AUG 21, 2018
T cells Trapped by Brain Cancer
Brain tumors prevent T cells from escaping the bone marrow by altering levels of the S1P1 protein....
OCT 08, 2018
Immunology
OCT 08, 2018
Natural Killer Cells to Aid in Cancer Therapy
Researchers utilize nanoparticles to stimulate NK cells that induce tumor cells to express PDL1, a protein involved in immune response messaging...
Loading Comments...